Analysis by Age Group of Disease Outcomes in Patients with Psoriatic Arthritis: A Cross-Sectional Multicentre Study

In this report, we have analysed disease outcomes in PsA by age groups.MethodsThis cross-sectional, multicentre study included 227 PsA patients under biological and non-biological systemic therapies. The study population was divided into four categories by age:    65 years. Physical functioning, disease activity, remission rates and disease impact were compared.ResultsThirty-one patients (13.7%) were under 40  years, 26.9% (n = 61) were 40–49 years, 26.4% (n = 60) were 50–65 years and 33.0% (n = 75) were patients >  65 years. Compared with the other age groups, disease duration was significantly higher in subjects older than 65 years (p 
Source: Drugs and Aging - Category: Geriatrics Source Type: research

Related Links:

Authors: Di Carlo M, Muto P, Benfaremo D, Luchetti MM, Atzeni F, Salaffi F Abstract OBJECTIVE: To evaluate the prevalence and factors associated with the neuropathic pain features in a cohort of patients with psoriatic arthritis (PsA). METHODS: A cross-sectional evaluation was conducted in consecutive patients suffering from PsA with prevalent peripheral joint involvement, referring to three rheumatological centers. For each patient a comprehensive assessment of disease activity, physical function, and disease impact was carried out. The presence of comorbid fibromyalgia syndrome (FMS) was evaluated. Acute phas...
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
The authors regret “The affiliations of the first author, Carlos Manuel Feced Olmos, are 1. Servicio de Reumatología, Hospital Universitario y Ploitécnico la Fe, Spain and 2. Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain”.
Source: Clinical Biomechanics - Category: Orthopaedics Authors: Tags: Corrigendum Source Type: research
This issue of the Rheumatic Disease Clinics of North America has broken ground in the area of process management of our diseases. The remarkable success of the treat-to-target approach in rheumatoid arthritis has led to increased speculation: can it be applied to our other rheumatic diseases, which may be more heterogeneous (in some cases) or where the targets are less obvious or more multidimensional? The assumption that control of inflammation, by its very nature, can lead to the optimum result of damage prevention makes intuitive sense, but at what level is the inflammation judged to be important? Should we use highly s...
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Tags: Foreword Source Type: research
This issue of the Rheumatic Disease Clinics of North America has broken ground in the area of process management of our diseases. The remarkable success of the treat to target approach in rheumatoid arthritis has led to increased speculation: can it be applied to our other rheumatic diseases, which may be more heterogeneous (in some cases) or where the targets are less obvious or more multidimensional? The assumption that control of inflammation, by its very nature, can lead to the optimum result of damage prevention makes intuitive sense, but at what level is the inflammation judged to be important? Should we use highly s...
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Tags: Foreword Source Type: research
CONCLUSION: Patients with PsA have a significant economic burden on the healthcare system. Functional status is highly correlated with costs and appears to be driven mainly by the cost of secondary care consultations. Results were similar to previous studies in rheumatoid arthritis populations. PMID: 31416922 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
AbstractJuvenile idiopathic arthritis is the most common chronic rheumatic disease of childhood resulting in disability in untreated cases. Disease modifying anti-rheumatic drugs form the first-line treatment in JIA. However, the data about leflunomide (LFN) in treatment of JIA is limited. We reviewed the medical files of JIA patients who were followed-up regularly and had received LFN. A total of 38 patients were included to the study. Among them, 24 had oligoarticular JIA, eleven had polyarticular JIA, two had ERA and one had psoriatic arthritis. 36 were initially treated with methotrexate and two patients diagnosed with...
Source: Rheumatology International - Category: Rheumatology Source Type: research
CONCLUSION: In this study, switching to a second or third TNFi was associated with significantly lower drug survival and response rates for patients with axial and peripheral PsA subtypes. More successful therapeutic approaches will require considering the impact of gender and obesity on TNFi effectiveness. PMID: 31371659 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
CONCLUSION: Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months. PMID: 31371650 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
The objective of this study was to develop a model to predict the clinical response at 6 months in patients with PsA starting the anti-tumour necrosis factor-α golimumab. METHODS: This prospective observational study explored a range of factors, including demographic data and baseline characteristics of the disease, measures of disease activity and functional disability, and potential laboratory biomarkers in the prediction of response, defined as the achievement of modified-minimal disease activity (mMDA), to golimumab in PsA patients. RESULTS: We studied 151 PsA patients starting golimumab because of their ...
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
In patients with PsA involving the hands, structural alterations of the dominant hand assessed by conventional x-ray and ultrasound are associated with loss of strength measured objectively with dynamometry and greater disability also studied subjectively using the HAQ.
Source: Clinical Biomechanics - Category: Orthopaedics Authors: Source Type: research
More News: Arthritis | Corticosteroid Therapy | Disability | Geriatrics | Psoriatic Arthritis | Rheumatology | Statistics | Study